Abstract
Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy.
Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery.
Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting.
Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.
Keywords: AIDS, bioavailability, HIV, lymphatic targeting, nanoparticles, therapeutic efficacy.
Recent Patents on Nanotechnology
Title:Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Volume: 10 Issue: 2
Author(s): Yogendra Nayak, Kiran Avadhani, Srinivas Mutalik and Usha Y. Nayak
Affiliation:
Keywords: AIDS, bioavailability, HIV, lymphatic targeting, nanoparticles, therapeutic efficacy.
Abstract: Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy.
Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery.
Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting.
Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.
Export Options
About this article
Cite this article as:
Nayak Yogendra, Avadhani Kiran, Mutalik Srinivas and Y. Nayak Usha, Lymphatic Delivery of Anti-HIV Drug Nanoparticles, Recent Patents on Nanotechnology 2016; 10 (2) . https://dx.doi.org/10.2174/1872210510999160414150818
DOI https://dx.doi.org/10.2174/1872210510999160414150818 |
Print ISSN 1872-2105 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4020 |
Call for Papers in Thematic Issues
Advances in Vanadium and Titanium Resources for High-performance Materials via Nanostructuring and Nanoengineering (updated BMS-NANOTEC-2023-HT-31)
Vanadium and titanium-based materials are ideal candidates for structural and functional materials in aerospace, biomedical engineering, optics, catalysis, energy storage and conversion etc. Vanadium/titanium-based alloys, compounds and materials have a large family with different chemical compositions, dimensions, structures/morphologies, and chemical/physical/mechanical properties, which provides huge opportunities for the development of emerging ...read more
Green Nanotechnology and Nanomaterials for a Sustainable Environment
Green nanotechnology (GN) might wind up being the most efficient platform for achieving the goals of the 2030 Agenda. The goal of GN is to create goods and procedures that are secure, energy-efficient, waste-free, and emit fewer greenhouse gases. Such goods and procedures use renewable resources, and/or their environmental impact ...read more
Nano-coatings and Nanoscale Composites for Hazardous Environments
Automobile, defence, and aerospace sectors need lightweight material for fuel efficiency and lower emissions. Often these materials are added with nanoscale reinforcements or have to be coated with nanomaterials to improve the scratch resistance, self-healing behaviour and corrosion and wear resistance and are all much needed for hazardous environments without ...read more
NANOSTRUCTURED NEUROMORPHIC DEVICES: TOWARDS IN MATERIA COMPUTING
The efforts pursued in the last decade to build up brain-inspired systems with electronic hardware solutions to solve complex data processing tasks, have leaded to the development of a new generation of devices, as memristor crossbar arrays, and their different applications became more and more reliable. One of the basic ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Cellular and Humoral Responses following Minimally Invasive Surgery: Role of Reactive Oxygen Species
Current Metabolomics Targeting Histone Deacetylase Inhibitors for Anti-Malarial Therapy
Current Topics in Medicinal Chemistry miRNAs in Bone Development
Current Genomics A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer
Current Drug Targets The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Sphere Formation Assay is not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line
Current Stem Cell Research & Therapy NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets “Momordica balsamina: A Medicinal and Neutraceutical Plant for Health care Management”. Comments: Biotechnological Potential of M. balsamina Revealed
Current Pharmaceutical Biotechnology